IMMUNOHISTOCHEMISTRY, CD 5

The IHC – CD5 (Cluster of Differentiation 5) test is an immunohistochemistry-based diagnostic assay used to detect CD5 protein expression in tissue samples. CD5 is a surface glycoprotein primarily expressed on T-lymphocytes and a subset of B-lymphocytes, making it an important marker in hematopathology.

This test plays a crucial role in identifying and classifying lymphoid malignancies, especially those involving abnormal T-cell or B-cell populations. CD5 is particularly significant in diagnosing conditions such as mantle cell lymphoma, chronic lymphocytic leukemia (CLL), and other non-Hodgkin lymphomas.

Benefits of the Test

• Helps identify T-cell and B-cell lymphoid malignancies
• Assists in classification of leukemia and lymphoma subtypes
• Supports differentiation between reactive and malignant lymphoid proliferation
• Improves accuracy in hematological cancer diagnosis
• Guides appropriate treatment planning in oncology

Why Doctors Recommend This Test

Doctors recommend the IHC CD5 test when there is suspicion of blood cancers or lymph node disorders. It is commonly used in:

• Evaluation of lymph node enlargement
• Suspected leukemia or lymphoma cases
• Bone marrow biopsy analysis
• Classification of non-Hodgkin lymphoma
• Differentiation of mantle cell lymphoma and CLL

CD5 expression pattern is essential in immunophenotyping panels and is often used along with markers like CD20, CD3, CD23, and Cyclin D1 to achieve a precise diagnosis.

Preparation Before Test

No special preparation is required from the patient. Important considerations:

• The test is performed on biopsy or bone marrow tissue samples
• No fasting or medication restrictions for patients
• Clinical history and previous reports are important for interpretation

Normal Reporting Time

The typical reporting time is 3 to 5 working days, depending on laboratory workload and specimen complexity.

Who Should Take This Test

• Patients with suspected lymphoma or leukemia
• Individuals with persistent lymph node enlargement
• Abnormal blood counts suggestive of hematological malignancy
• Bone marrow evaluation cases
• Patients undergoing cancer staging or classification

The IHC CD5 test is a vital tool in modern hematopathology, helping pathologists accurately identify lymphoid cell lineage and differentiate between benign and malignant conditions. This ensures precise diagnosis and appropriate treatment planning.